Fw: Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report.

[1]Diagn Cytopathol. 2008 Jun 4; 36(7): 512-515
Ikeda K, Suzuki T, Tate G, Mitsuya T

Well-differentiated papillary mesothelioma (WDPM), a distinct subtype of diffuse malignant mesothelioma, usually occurs in the peritoneum and is seen most commonly in women of reproductive age. Histologic features of WDPM include papillary growth and stout fibrous cores surrounded by a single layer of tumor cells. We present the case of a 73-year-old woman without subjective symptoms who showed signs of peritoneal effusion during a routine examination and for whom cytologic examination of the ascitic fluid was performed. Many spherical clusters, with a smooth external surface composed of a single layer of uniform cuboidal cells, were observed. Within each cluster, a collagenous ball showed light green Papanicolaou staining. Immunohistochemistry of surgical specimens showed tumor cells positive for calretinin, D(2)-40, and HBME-1 staining. The histologic diagnosis was WDPM. The identification of a collagenous ball within these clusters is a useful cytologic finding for the diagnosis of WDPM. WDPM should be suspected when numerous collagenous balls are present by effusion cytology and isolated cells are not. Diagn. Cytopathol. 2008;36:512-515. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18528881
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine.

[1]Oncology. 2008 Jun 3; 73(5-6): 426-429
Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME

We report the case of a 56-year-old patient with malignant pleural mesothelioma of epithelial type, who responded to second-line chemotherapy with lipoplatin plus gemcitabine. Diagnosis and staging of the disease was done by medical thoracoscopy with biopsies of the right pleura in December 2003, when he was treated with talc pleurodesis. Eighteen months later, he presented with pleural effusion of the left side and underwent first-line chemotherapy with cisplatin plus vinorelbine. After 8 cycles, the patient presented renal toxicity limiting further cisplatinum chemotherapy and disease progression with peritoneal invasion of the tumor and ascites. Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.



___
Source: http://www.hubmed.org/display.cgi?uids=18523361
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Pulmonary paragonimiasis with coincidental malignant mesothelioma.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: Pulmonary paragonimiasis with coincidental malignant mesothelioma.

[1]Intern Med. 2008; 47(11): 1027-31
Yamazaki M, Ohwada A, Miyaji A, Yamazaki H, Nara T, Hirai S, Fujii H, Uekusa T, Suzuki M, Iwase A, Takahashi K

A 72-year-old man patient was referred to our institution for evaluation and treatment of right pleural effusion. Eosinophilic pleural effusion and peripheral eosinophilia were identified during the course of hospitalization. Pulmonary paragonimiasis was confirmed by the presence of paragonimus-specific IgG antibodies for Paragonimus (P.) westermani and P. miyazakii in his serum. Although Praziquantel, a highly effective agent for the treatment of lung flukes was repeatedly administered, the pleural effusion did not subside and the patient's condition gradually deteriorated until his death due to circulatory insufficiency. Postmortem examination revealed malignant mesothelioma of the sarcomatous type encasing the right lung and heart. Cardiac involvement accompanied with old and recent-onset myocardial ischemic changes resulted in death of this patient. Here, we report a very rare case of malignant mesothelioma with a concomitant infection of parasitic lung fluke.



___
Source: http://www.hubmed.org/display.cgi?uids=18520115
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Metastases in malignant pleural mesothelioma: A new radiological appearance.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: Metastases in malignant pleural mesothelioma: A new radiological appearance.

[1]Respirology. 2008 May 29;
Fares M, Abbas O, Jamaleddine G, Bou-Khalil P

This report describes a patient with malignant pleural mesothelioma who presented with a right-sided pleural effusion and contralateral parenchymal metastases manifesting as alveolar opacities with air bronchograms. This radiological pattern of metastases has never been described before. The patient died from respiratory failure related to extensive parenchymal metastases, an outcome seldom reported with malignant pleural mesothelioma.



___
Source: http://www.hubmed.org/display.cgi?uids=18513248
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Underestimation of Low-Dose Radiation in Treatment Planning of Intensity-Modulated Radiotherapy.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: Underestimation of Low-Dose Radiation in Treatment Planning of Intensity-Modulated Radiotherapy.

[1]Int J Radiat Oncol Biol Phys. 2008 May 29;
Jang SY, Liu HH, Mohan R

PURPOSE: To investigate potential dose calculation errors in the low-dose regions and identify causes of such errors for intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: The IMRT treatment plans of 23 patients with lung cancer and mesothelioma were reviewed. Of these patients, 15 had severe pulmonary complications after radiotherapy. Two commercial treatment-planning systems (TPSs) and a Monte Carlo system were used to calculate and compare dose distributions and dose-volume parameters of the target volumes and critical structures. The effect of tissue heterogeneity, multileaf collimator (MLC) modeling, beam modeling, and other factors that could contribute to the differences in IMRT dose calculations were analyzed. RESULTS: In the commercial TPS-generated IMRT plans, dose calculation errors primarily occurred in the low-dose regions of IMRT plans (

___
Source: http://www.hubmed.org/display.cgi?uids=18513883
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [An autopsy case of diffuse pleural thickening presented respiratory impairment and benign asbestos pleurisy]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: [An autopsy case of diffuse pleural thickening presented respiratory impairment and benign asbestos pleurisy]

[1]Nihon Kokyuki Gakkai Zasshi. 2008 May; 46(5): 368-73
Morokawa N, Takayanagi N, Ubukata M, Kurashima K, Yoned K, Tsuchiy N, Miyahara Y, Yamaguchi S, Tokunaga D, Saito H, Yanagisawa T, Sugita Y, Kawabata Y

A 51-year-old man presented with back pain in 1997. He had a 30-year-history of occupational asbestos exposure. His chest CT showed bilateral pleural thickening and pleural effusion. The pleural effusion of the right thorax exhibited both elevated level of adenosine deaminase and increased numbers of lymphocytes. Antituberculous chemotherapy had no effect on the exudates. Progressive bilateral pleural thickening were found on chest CT, and pulmonary function tests showed severe restrictive ventilatory impairments since 1998. Thoracoscopic pleural biopsy was conducted in 2001 to exclude pleural malignant mesothelioma. No malignancy was found in pleural samples. After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy. In 2005, fibrotic changes were found in both lower lung fields in chest CT. He suffered from respiratory failure with carbon dioxide retention, and died in 2006. The autopsy disclosed asbestos-related lung diseases. We suspected that diffuse pleural thickening could be a major cause of fatal respiratory impairment in this case.



___
Source: http://www.hubmed.org/display.cgi?uids=18517012
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.

[1]Future Oncol. 2008 Jun; 4(3): 341-9
Beck AK, Pass HI, Carbone M, Yang H

Ranpirnase, originally isolated from oocytes of the northern leopard frog (Rana pipiens), is a member of the pancreatic RNase A superfamily of ribonucleases. Ranpirnase exerts antiproliferative and cytotoxic effects in vitro and in vivo and has been shown to act synergistically with different cancer therapeutic agents. The cytotoxic and cytostatic effects of ranpirnase are the consequence of tRNA degradation that results in the disruption of protein translation and the induction of programmed cell death (apoptosis). Ranpirnase has been shown to target malignant cells both in human cancer cell lines and in animal models, and has demonstrated efficacy in the treatment of several human cancers in clinical studies. Most clinical studies have been conducted in patients with malignant mesothelioma, and a confirmatory Phase IIIb trial is currently underway for the treatment of this disease. Owing to its selective destruction of malignant cells and favorable toxicology profile, ranpirnase is a promising antitumor agent with ideal attributes that are generally lacking in conventional cytotoxic drugs.



___
Source: http://www.hubmed.org/display.cgi?uids=18518759
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Malignant mesothelioma 2008.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:30 AM
Subject: Malignant mesothelioma 2008.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 303-9
Zervos MD, Bizekis C, Pass HI

PURPOSE OF REVIEW: Mesothelioma is an aggressive malignancy of the pleura with poor survival. There will be approximately 3000 cases of mesothelioma in the United States annually. Multimodality treatment including neoadjuvant chemotherapy in selected individuals followed by extrapleural pneumonectomy and radiation has been studied in recent trials for its effects on disease free and overall survival This review provides a general overview of malignant mesothelioma with a summary of the most significant articles from within the past year as well as from the past. RECENT FINDINGS: Areas of recent interest include the evaluation of osteopontin and mesothelin as new tumor markers for mesothelioma. New phase III trials have been performed to evaluate the use of combined chemotherapy regimens. SUMMARY: Malignant mesothelioma is a very difficult malignancy to treat. Patients with the disease usually have an occupational asbestos exposure, and in some, viral exposure with SV40. There have been many historical treatments including combinations of local control with surgery and radiation as well as attempts to prevent systemic failure with chemotherapy. Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.



___
Source: http://www.hubmed.org/display.cgi?uids=18520263
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc